No no Diffuse Aus and for No PBAC no for no Obinutuzumab Gazyva® 4 Yes large B-cell 1 None no funding NZ the application registration this registration lymphoma no no Aus and No Sept registration no Ofatumumab Arzerra® 2 Yes 1 None no funding NZ response 2014 for CLL in no registration Nov 2014 funding Breast cancer; stage 4 papillary Aus and Dec no Nov no Olaparib 3 Yes serous 3 None no funding no funding NZ 2015 registration 2016 registration carcinoma (BRCA1 mutation positive) $463 Metastatic no no per vial Paclitaxel Aus and pancreatic March 11 Yes 93 for the March no funding nanoparticle NZ cancer 2014 no no first 21 2014, second line funding funding vials listing Nov 2014 for Metastatic mCRC in outside no Aus and May no Panitumumab Vectibix® 5 Yes colorectal 2 None 2013/2014 funding no funding NZ 2008 registration cancer and restrictions extended March 2015
registration Obinutuzumab Gazyva® Aus and NZ 4 Yes Diffuse large B-cell lymphoma 1 None No for the No PBAC application no registration no for this no funding no registration Ofatumumab Arzerra® Aus and NZ 2 Yes No response 1 None Sept 2014 for CLL in Nov 2014 no no funding no no funding no registration Olaparib Aus and NZ 3 Yes Breast cancer; stage 4 papillary serous carcinoma (BRCA1 mutation positive) 3 None Dec 2015 no funding no registration Nov 2016 no funding no registration Paclitaxel nanoparticle Aus and NZ 11 Yes Metastatic pancreatic cancer second line 93 $463 per vial for the first 21 vials March 2014 March 2014, listing Nov 2014 no no funding no funding no no funding Panitumumab Vectibix® Aus and NZ 5 Yes Metastatic colorectal cancer 2 None May 2008 for mCRC in 2013/2014 and extended March 2015 outside funding restrictions no no funding no registration
1-s2.0-S0168851017303457-mmc1.docx